We're currently experiencing extremely high call volumes. We're very sorry for any inconvenience this might cause. If you need help with your account, please visit our Help Centre, or email us and we’ll get back to you as soon as we can. For more information and tips on managing your account online please visit www.hl.co.uk/coronavirus

We’re experiencing high call volumes, please check FAQs before calling.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Kodiak Sciences Inc (KOD) USD0.0001

Sell:$49.84 Buy:$50.07 Change: $3.40 (7.30%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $3.40 (7.30%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $3.40 (7.30%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Kodiak Sciences Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing therapeutics to treat ophthalmic diseases. The Company’s Antibody Biopolymer Conjugate (ABC) platform focuses on merging the fields of antibody-based and chemistry-based therapies. The Company in addition to its lead product candidate, KSI-301, is a molecule for age-related macular degeneration and diabetic retinopathy. The Company has leveraged its ABC platform to build a pipeline of product candidates in various stages of development including KSI-501, a dual inhibitor ABC for the treatment of neovascular retinal diseases, such as wet AMD and diabetic retinopathy.

Contact details

2631 Hanover St
United States
+1 (650) 2810850

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$2.07 billion
Shares in issue:
44.42 million
United States
US dollar

Key personnel

  • Victor Perlroth
    Chairman of the Board, President, Chief Executive Officer
  • John Borgeson
    Chief Financial Officer, Senior Vice President, Secretary
  • Hong Liang
    Senior Vice President - Discovery Medicine
  • Jason Ehrlich
    Chief Medical Officer and Chief Development Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.